NGS Oncology Market Forecast: What to Expect by 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The NGS Oncology Market By 2029?

The ngs oncology market has experienced significant expansion in recent years. Its valuation is anticipated to climb from $17.36 billion in 2024 to $19.33 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 11.3%. This historical expansion is primarily driven by factors such as an escalation in cancer occurrence, increasing investigations into cancer genomics, heightened public understanding, the development of healthcare infrastructure, and an escalating need for individualized medical approaches.

The NGS oncology market is projected to experience substantial growth in the upcoming years. It is anticipated to reach $29.64 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 11.3%. This expansion during the forecast period is primarily attributable to factors such as the increasing development of companion diagnostics, the rising prevalence of cancer, heightened government and healthcare investments, the broadening of clinical applications, and the growing appeal of targeted therapies. Key trends expected in the forecast period include the integration of artificial intelligence and machine learning, advancements in single-cell sequencing, enhanced sequencing platforms, developments in liquid biopsy technology, and breakthroughs in high-throughput sequencing platforms.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24337&type=smp

Which Drivers Are Supporting Growth Of The NGS Oncology Market?

The increasing occurrence of cancer is projected to stimulate the growth of the NGS oncology market in the coming years. Cancer is a condition characterized by the uncontrolled proliferation of abnormal cells that can spread throughout the body, impeding normal physiological processes. The rising incidence of cancer is largely due to demographic shifts towards older populations, given that the risk of developing cancer escalates with age. NGS oncology plays a crucial role in managing this rising cancer prevalence by enabling prompt detection, precise diagnostics, and customized treatment plans through detailed genetic analysis of tumors. For example, according to the American Cancer Society, a U.S.-based nonprofit organization, about 20 million new cancer cases were documented globally in 2022, resulting in 9.7 million fatalities; primarily driven by population expansion, the worldwide cancer burden is anticipated to reach 35 million cases by 2050. Thus, the escalating prevalence of cancer will serve as a key driver for the expansion of the NGS oncology market.

What Are The Segment Types Shaping The NGS Oncology Market?

The ngs oncologymarket covered in this report is segmented –

1) By Sequencing Technology: Targeted Sequencing; Genomics; Transcriptomics; Epigenomics

2) By Offering: Platform; Kits; Services

3) By Workflow: Pre-Sequencing; Sequencing; Data Analysis

4) By Application: Genetic Screening; Hereditary Genetic Testing; Hematological Malignancies; Solid Tumors; Other Applications

5) By End User: Hospitals And Clinics; Clinical Research Organizations (CROs); Academic And Research Institutes; Pharmaceutical And Biotechnology Companies; Other End Users

Subsegments:

1) By Targeted Sequencing: Whole Exome Sequencing (WES); Amplicon-Based Sequencing; Hybridization-Based Sequencing

2) By Genomics: Whole Genome Sequencing (WGS); Structural Variant Detection; Copy Number Variation (CNV) Analysis

3) By Transcriptomics: RNA Sequencing; Single-Cell Transcriptomics; Non-coding RNA Analysis

4) By Epigenomics: DNA Methylation Sequencing; Chromatin Immunoprecipitation Sequencing; Histone Modification Analysis

What Long-Term Trends Will Shape The Future Growth Of The NGS Oncology Industry?

Leading companies in the NGS oncology market are concentrating on developing advanced solutions, such as liquid biopsy research assays, to facilitate non-invasive and real-time cancer detection and monitoring through the analysis of circulating tumor DNA. A liquid biopsy research assay is defined as a diagnostic test designed to analyze biological fluids, like blood, for detecting genetic mutations or other molecular markers associated with cancer, thus enabling non-invasive cancer detection and monitoring. For example, in August 2024, Illumina Inc., a US-based biotechnology firm specializing in next-generation sequencing (NGS) technology, expanded its oncology product line for users of its NovaSeq X Series. The company now provides the newly validated high-throughput TruSight Oncology 500 (TSO 500 HT) and the updated TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) liquid biopsy research assay. These improved assays allow laboratories to extend their oncology research capabilities for both tissue and liquid biopsy samples, offering benefits such as enhanced sequencing efficiency, shorter run times, and the unprecedented ability to process larger sample volumes on the NovaSeq X Series.

Who Are The Prominent Global Companies Shaping The NGS Oncology Market?

Major companies operating in the NGS oncology market are Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Eurofins Scientific SE, Illumina Inc., Qiagen N.V., Tecan Trading AG, Myriad Genetics, Takara Bio Inc., Beijing Genomics Institute (BGI), Caris Life Sciences, Foundation Medicine, Paradigm Diagnostics, Pacific Bioscience, Horizon Discovery Group plc , Creative-Biolabs, Xcelris Labs Ltd., Partek Inc., 4baseCare, SciGenom Labs Pvt. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/ngs-oncology-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The NGS Oncology Market?

North America was the largest region in the NGS oncology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the NGS oncology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The NGS Oncology Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24337&type=smp

Browse Through More Reports Similar to the Global NGS Oncology Market 2025, By The Business Research Company

Oncology Information Systems Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/oncology-information-systems-global-market-report

Veterinary Oncology Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/veterinary-oncology-global-market-report

Hemato Oncology Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hemato-oncology-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795